OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

Research News

Research Round-Up: 11th Biennial Ovarian Cancer Research Symposium September 12-13, 2014 in Seattle, Washington

By Annie Ellis Ovarian Cancer survivor and advocate, OCRFA Scientific Advisory Committee Member The Biennial Ovarian Cancer Research Symposium is presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. The goal of the Symposium is to bring together clinicians... 

Oral Contraceptives Play Role in Decline of Deaths from Ovarian Cancer

(September 12, 2016) The European Society of Medical Oncology published a study last week that indicated the reasons for a decrease in deaths from ovarian cancer in both young women and post-menopausal women. From 2002 to 2012, death rates fell by 10% in the European Union and by 16% in the United States,... 

Study Reveals Potential Importance of Studying Cell Lineage

(September 9, 2016) Nature Communications recently published a study that used proteomics, or the study of proteins, to identify the lineage of 26 different ovarian cancer cell lines. Identifying where the cell lines originate can help us categorize a full spectrum of tumors and lead us to understand... 

OCRFA Applauds Food and Drug Administration’s Statement on Ovarian Cancer Screening Test

For Immediate Release September 7, 2016 Contact: Lisa Mauti lmauti@ocrfa.org 443-845-2626 Today the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research... 

SGO and ASCO Agree on Guidelines for Common Type of Ovarian Cancer

(August 16, 2016) While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and followed by surgery. Last... 

Impact of Genetic Counseling on Testing and Surgical Prevention in High Risk Women

(Aug 1. 2016) Results of a study reported last month in Cancer show that routine referral of women at high risk for ovarian cancer to genetic counseling promotes genetic testing and prophylactic surgery. Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an... 

Women Still Getting CA-125 and CT Testing After Ovarian Cancer, Despite Lack of Clear Benefit

(July 28, 2016)  A study published recently in JAMA Oncology showed that CA-125 tests and CT scans are routinely used in ovarian cancer surveillance testing, even though evidence has shown there is no clinical benefit to using these tests. There is no consensus on how to follow a patient in remission... 

New Treatment Shows No Benefit for Clear Cell Carcinoma     

(July 18, 2016) The first randomized phase III clinical trial to compare irinotecan and cisplatin with paclitaxel plus carboplatin in patients with clear cell carcinoma (CCC) of the ovary found no significant survival benefit between the groups. The findings of the study, which was conducted in Japan,... 

Study Finds Many Ovarian Cancer Patients Going Untreated

(July 6, 2016) Gynecologic Oncology recently published a study that found that, although surgery leads to longer survival rates, many ovarian cancer patients are not undergoing surgery, and some are not being treated at all. The researchers analyzed data from more than 210,000 women diagnosed with ovarian... 

The Effect of Oral Contraceptives on Ovarian Cancer

(June 23, 2016) The Journal of Clinical Oncology recently published a study on the role of oral contraceptives (OC) on ovarian cancer prevention. The study, which analyzed data from 21 studies with 5, 584 cases of ovarian cancer, concluded that OC reduced the risk of a variety of invasive ovarian cancers. The...